The case of Bayer acarbose's suicide price reduction seems to confirm this point. Bayer said in its performance report for the first half of 2020 that the global sales of diabetes drug betapin (generic name acarbose) decreased by 73.8%, mainly due to the policy of purchasing with quantity in China market, and the increase in sales of betapin could not offset the sharp price reduction of the drug.
In sharp contrast, Pfizer. At the end of 20 18, Pfizer's star drugs Lipitor and Luohuoxi were eliminated in the first 4+7 quantity purchase. 2065438+September 2009, Pfizer purchased the 4+7 expansion belt and failed to win the bid.
However, in the financial data of the first half of 2020, the sales volume of Lipitor and Locust in China has increased significantly year-on-year, and the sales volume has returned to the level before centralized procurement.
Another person in the medical field told reporters that foreign pharmaceutical companies need to weigh the differences in drug pricing at home and abroad, and it is difficult for the headquarters to authorize them to compete at extremely low prices, and the price reduction can not be consistent with domestic enterprises. At the same time, its strong market position does enable it to support for a period of time after losing the centralized procurement market, instead of dying or dying like many domestic enterprises.
Extended data
The quotation of multinational pharmaceutical companies is basically invalid:
Judging from the selection results, only two imported drugs were selected, and the rest were all out. Moreover, in the quotation, 15 drugs are overpriced, which does not show the sincerity of price reduction, and is even pointed out by the industry as a "demonstration".
For example, Merck gave up desloratadine oral sustained-release dosage forms at a price exceeding 1.56 times; Roche gave up the competition of capecitabine oral sustained-release dosage form by 2.23 times exceeding the price limit; Lilly gave up the competition of olanzapine orally disintegrating tablets by exceeding the price limit 1 times; What's more, GSK's lamivudine basically maintains the original price, exceeding the price limit by more than 80 times.
Judging from the rules of joint procurement release, this declared price is only valid if the declared price of the company is less than or equal to the highest effective declared price. This also means that the quotations of the above-mentioned multinational pharmaceutical companies are basically invalid.